In patients with solid cancers, tumor regression was noted following therapy with MDX-1106 (Medarex, Princeton, NJ, USA), an αCD279 IgG4 Ab, further demonstrating that the CD279 pathway plays a crucial role in cancer progression [2]. The gene discussed is PDCD1; the disease is cancer.